T cell leukemia control via Ras-Raf pathway inhibition with peptides
RATIONALE: RAS-RAF-MEK-ERK pathway has been considered a promising target for anticancer therapy. However, tumor cells may develop resistance against such drugs via hyperactivation of N-Ras, which explains why novel therapeut-ic approaches. In this sense, the Institute Curie- Université Pierre et Ma...
| Autores principales: | , , |
|---|---|
| Formato: | Articulo |
| Lenguaje: | Inglés |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | http://sedici.unlp.edu.ar/handle/10915/78709 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652266/ |
| Aporte de: |
| id |
I19-R120-10915-78709 |
|---|---|
| record_format |
dspace |
| institution |
Universidad Nacional de La Plata |
| institution_str |
I-19 |
| repository_str |
R-120 |
| collection |
SEDICI (UNLP) |
| language |
Inglés |
| topic |
Ciencias Médicas peptides cancer leukemia mice |
| spellingShingle |
Ciencias Médicas peptides cancer leukemia mice Marín, Gustavo Horacio Bruzzoni Giovanelli, H. Schinella, Guillermo Raúl T cell leukemia control via Ras-Raf pathway inhibition with peptides |
| topic_facet |
Ciencias Médicas peptides cancer leukemia mice |
| description |
RATIONALE: RAS-RAF-MEK-ERK pathway has been considered a promising target for anticancer therapy. However, tumor cells may develop resistance against such drugs via hyperactivation of N-Ras, which explains why novel therapeut-ic approaches. In this sense, the Institute Curie- Université Pierre et Marie Curie (Paris 6) designed peptides in order to disturb Ras/Raf interaction which showed pro-apoptotic properties. These peptides were patented as WO2015001045 A2 (PCT/EP2014/064243)5.
OBJECTIVE: In order to check the anti-tumoral action of WO2015001045 A2 peptides in a very aggressive BALB/c mice spontaneous leukemia called LB, we performed the present study.
METHOD & RESULTS: 50 BALB/c mice inoculated with 106 LB tumor cells were randomly assigned either to control (placebo) or treatment group (that daily received 3 mg of peptide per kg of mice) during 30 days. By day 15 only 24% of the control group was alive vs. 100% of the treatment group. The average survival in treated group was 20,27 days while in control group the mean survival was 15,48 days. Either bone marrow, spleen or axillary nodes demonstrated a higher level of malignant T cell presence compare with treated group (89,78% ; 95,64% & 77,68% versus 72,45%, 80,23% & 63.44% respectively for each organ inspected.
DISCUSSION: Our study demonstrated an improvement in survival curves in mice model affected by spontaneous T lymphoid leukemia when peptides WO2015001045 A2 were used. These peptides might be a valid option to become part of the therapeutic armory for malignant lymphoproliferative diseases control. |
| format |
Articulo Articulo |
| author |
Marín, Gustavo Horacio Bruzzoni Giovanelli, H. Schinella, Guillermo Raúl |
| author_facet |
Marín, Gustavo Horacio Bruzzoni Giovanelli, H. Schinella, Guillermo Raúl |
| author_sort |
Marín, Gustavo Horacio |
| title |
T cell leukemia control via Ras-Raf pathway inhibition with peptides |
| title_short |
T cell leukemia control via Ras-Raf pathway inhibition with peptides |
| title_full |
T cell leukemia control via Ras-Raf pathway inhibition with peptides |
| title_fullStr |
T cell leukemia control via Ras-Raf pathway inhibition with peptides |
| title_full_unstemmed |
T cell leukemia control via Ras-Raf pathway inhibition with peptides |
| title_sort |
t cell leukemia control via ras-raf pathway inhibition with peptides |
| publishDate |
2017 |
| url |
http://sedici.unlp.edu.ar/handle/10915/78709 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652266/ |
| work_keys_str_mv |
AT maringustavohoracio tcellleukemiacontrolviarasrafpathwayinhibitionwithpeptides AT bruzzonigiovanellih tcellleukemiacontrolviarasrafpathwayinhibitionwithpeptides AT schinellaguillermoraul tcellleukemiacontrolviarasrafpathwayinhibitionwithpeptides |
| bdutipo_str |
Repositorios |
| _version_ |
1764820486490947586 |